X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/03/27/2853589/0/en/Celcuity-Inc-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.bayer.com/media/en-us/bayer-pharmaceuticals-advances-next-generation-of-blockbuster-medicines/
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-darolutamide-tablets-33829.pdf
https://www.globenewswire.com//news-release/2023/08/22/2729994/0/en/Celcuity-Enters-into-a-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Bayer-to-Provide-Nubeqa-darolutamide-for-Planned-Phase-1b-2-Clinical-Trial.html
https://www.fiercepharma.com/pharma/bayers-blockbuster-hopeful-nubeqa-astrazenecas-farxiga-pick-nods-englands-nice
https://www.fiercepharma.com/pharma/rough-quarter-bayers-duo-nubeqa-kerendia-continue-excel
https://www.globenewswire.com/news-release/2023/03/23/2633203/0/en/Orion-and-Bayer-expand-clinical-development-program-for-darolutamide-in-prostate-cancer.html
https://www.globenewswire.com/news-release/2023/03/20/2629930/0/en/Darolutamide-approved-for-additional-prostate-cancer-indication-in-China.html
https://www.globenewswire.com/news-release/2023/02/27/2615685/0/en/Darolutamide-receives-approval-for-additional-prostate-cancer-indication-in-Japan.html
https://www.globenewswire.com/news-release/2023/01/27/2596803/0/en/Positive-CHMP-opinion-for-darolutamide-in-combination-with-docetaxel-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer.html
https://www.globenewswire.com/news-release/2023/01/27/2596803/0/en/Positive-CHMP-opinion-for-darolutamide-in-combination-with-docetaxel-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer.html
https://www.pharmaceutical-technology.com/news/nhs-bayer-darolutamide-prostate-cancer/
https://pharmaphorum.com/news/mhra-nhs-england-make-available-new-prostate-cancer-treatment/
https://www.fiercepharma.com/pharma/bayers-blockbuster-hopeful-nubeqa-shifts-later-stage-prostate-cancer-under-uk-early-access
https://www.bayer.com/en/ca/health-canada-approves-additional-indication-for-nubeqar
https://www.bayer.com/media/en-us/new-arasens-data-reinforce-strong-tolerability-profile-of-darolutamide-plus-adt-and-docetaxel-without-compromising-quality-of-life-for-patients-with-mhspc/
https://www.fiercepharma.com/pharma/look-out-pfizer-bayers-nubeqa-coming-xtandis-prostate-cancer-crown
https://www.globenewswire.com/news-release/2022/08/08/2493531/0/en/U-S-FDA-approves-additional-indication-of-darolutamide-in-combination-with-docetaxel-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer-mHSPC.html
https://media.bayer.com/baynews/baynews.nsf/id/Darolutamide-androgen-deprivation-therapy-docetaxel-demonstrates-consistent-overall-survival?OpenDocument&sessionID=1660127120
https://www.globenewswire.com/news-release/2022/05/03/2434475/0/en/U-S-FDA-accepts-supplemental-new-drug-application-sNDA-and-grants-priority-review-for-additional-indication-of-darolutamide.html
https://www.fiercepharma.com/pharma/bayer-tees-up-3-way-battle-against-pfizer-astellas-johnson-johnson-nubeqa-prostate-cancer
https://www.pharmatimes.com/news/data_day_trial_results_deliver_hope_for_prostate_cancer_patients_1387889
https://www.fiercepharma.com/pharma/bayer-pads-blockbuster-case-for-nubeqa-metastatic-prostate-cancer-win
https://www.globenewswire.com/news-release/2021/12/03/2345595/0/en/ARASENS-trial-with-darolutamide-in-combination-with-docetaxel-and-androgen-deprivation-therapy-meets-primary-endpoint-of-significantly-increasing-overall-survival-in-patients-with-.html
https://www.raps.org/news-and-articles/news-articles/2021/8/fda-finalizes-guidance-on-metastasis-free-survival
https://www.prnewswire.com/news-releases/essa-pharma-announces-clinical-collaboration-agreement-with-bayer-to-evaluate-the-combination-of-epi-7386-and-darolutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-301278550.html
https://www.fiercepharma.com/marketing/speak-up-doc-bayer-s-ami-voice-assistant-talks-prescription-drug-info-for-physicians
https://media.bayer.com/baynews/baynews.nsf/id/816B47BBE42AC9C5C125863A00459D01?open&ref=irrefndcd
http://www.pharmafile.com/news/563499/scottish-medicines-consortium-greenlights-nubeqa-prostate-cancer
http://www.pharmafile.com/news/562318/bayers-nubeqa-secures-nice-recommendation-hormone-relapsed-prostate-cancer-risk-metastas
https://www.businesswire.com/news/home/20200909006068/en/New-England-Journal-Medicine-Publishes-Final-Data
https://www.iqwig.de/en/press/press-releases/darolutamide-in-prostate-cancer-indication-of-considerable-added-benefit.13174.html
https://en.prnasia.com/releases/global/kangpu-to-present-two-posters-at-the-2020-american-association-for-cancer-research-aacr-annual-meeting-282967.shtml
https://www.globenewswire.com/news-release/2020/05/20/2036168/0/en/Sales-of-darolutamide-started-in-the-EU-and-Japan-Orion-receives-total-of-EUR-28-million-milestones.html
https://www.ema.europa.eu/en/documents/overview/nubeqa-epar-medicine-overview_en.pdf
http://www.pmlive.com/pharma_news/bayer_gets_eu_nod_for_prostate_cancer_drug_nubeqa_1332671
http://www.pharmatimes.com/news/nubeqa_authorised_in_europe_for_certain_prostate_cancer_patients_1332707
http://www.pharmafile.com/news/539968/bayer-and-orions-nubeqa-shows-strong-overall-survival-benefit-castration-resistant-prost
https://www.fiercepharma.com/marketing/bayer-s-nubeqa-gets-better-chance-at-challenging-pfizer-and-j-j-prostate-cancer-key
Market Place
Share 
